121 Richmond Street West, Penthouse Suite, 1300
Toronto, Ontario M5H 2K1

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

TO BE HELD ON MAY 19, 2026

Time and Date:	09:00 a.m. (Eastern Time) on May 19, 2026

NOTICE IS HEREBY GIVEN that the annual and special meeting (the "**Meeting**") of the shareholders (the "**Shareholders**") holding common shares of Psyence Group Inc. (the "**Company**") will be held at the offices of Bayline Capital Partners Inc., Suite (1300) - 121 Richmond Street West, Toronto, Ontario, M5H 2K1 on Tuesday, May 19, 2026 at 9:00 a.m. (Eastern Time) for the following purposes:

1. to receive the audited financial statements of the Company for the financial year ended March 31, 2024 and March 31, 2025, together with the auditor's reports, respectively;

2. to elect the directors of the Company to hold office until their successors are elected or appointed;

3. to:

    (a) appoint MNP LLP, Chartered Professional Accountant, as auditor of the Company to hold office until the earlier of (i) the completion or termination of the Amalgamation (as defined below), and (ii) the close of the next annual meeting and to authorize the directors of the Company to fix their remuneration; and

    (b) conditionally, upon completion of the Amalgamation (as defined below), appoint Jones & O'Connell LLP as auditor of the Resulting Issuer (as defined below) for the ensuing year and to authorize the directors of the Resulting Issuer to fix their remuneration;

4. conditionally, upon completion of the Amalgamation, to consider and, if deemed advisable, to pass, with or without variation, an ordinary resolution approving the new securities incentive plan of the Resulting Issuer in accordance with the provisions of the Amalgamation Agreement (as defined below);

5. conditionally, upon completion of the Amalgamation, to consider and, if deemed advisable, to pass, with or without variation, a special resolution approving the consolidation of the common shares of the Company in accordance with the provisions of the Amalgamation Agreement;

6. conditionally, upon completion of the Amalgamation, to consider and, if deemed advisable, to pass, with or without variation, a special resolution approving an amendment to the Company's articles to change the Company's name to GoldCoast Resource Corp. in accordance with the provisions of the Amalgamation Agreement;

7. to consider and, if deemed advisable, to elect, concurrently with the completion of the Amalgamation, the directors of the Resulting Issuer to hold office until their successors are elected or appointed;

8. to consider and, if deemed advisable, pass an ordinary resolution of the disinterested Shareholders approving the Company's proposed Change of Business/Fundamental Change under Policy 8 of the Canadian Securities Exchange, being the transition of the Company's business from biotechnology to natural resource exploration (the "**Resulting Issuer**"), pursuant to an amalgamation agreement dated November 21, 2025, as amended February 24, 2026 and April 13, 2026, respectively (the "**Amalgamation Agreement**") among the Company, Psyence Therapeutics Corp., a wholly owned subsidiary of the Company, ("**Psyence Subco**") and GoldCoast Resources Corp. ("**GoldCoast**") entered into in order to complete the amalgamation of GoldCoast and Psyence Subco pursuant to the provisions of the *Business Corporation Act* (Ontario) (the "**Amalgamation**"); and

9. to transact such other business as may properly come before the Meeting or any adjournments thereof.

The record date for determining Shareholders entitled to receive this notice of annual and special meeting and to vote at the Meeting (or any postponement or adjournment of the Meeting) is the close of business on Friday, April 17, 2026.

Particulars of the foregoing matters are set forth in the management information circular of the Company (the "**Circular**") accompanying this notice (the "**Notice of Meeting**"), enclosed form of proxy (the "**Proxy**") and a Financial Statement Request Form. This Notice of Meeting and the accompanying Circular have been sent or been made available to each director of the Company, each Shareholder entitled to notice of the Meeting and the auditors of the Company. The accompanying Circular provides information relating to the matters to be addressed at the Meeting and is incorporated into this Notice of Meeting.

This Notice of Meeting is accompanied by the Proxy, the Circular and a Financial Statement Request Form. These materials contain detailed voting instructions and information about the matters to be decided at the Meeting. As a Shareholder, you should read the accompanying materials carefully. If you are a Shareholder and wish to be represented by proxy at the Meeting (or any postponement or adjournment of the Meeting), you should follow the voting instructions provided with your Proxy. To be valid, submitted Proxies must be received on or before 9:00 a.m. (Toronto time) on Thursday, May 14, 2026, to the Company's transfer agent and registrar, Odyssey Trust Company, Attention: Stacey Diocampo, Suite 702 – 67 Yonge Street, Toronto, Ontario, M5E 1J8. If you are a Registered Shareholder (please see the accompanying Circular for a definition) and wish to vote in person at the Meeting (or any postponement or adjournment of the Meeting), you will be asked to register for the Meeting by identifying yourself at the registration desk at the Meeting.

DATED on the 22nd day of April, 2026.

By Order of the Board of Directors

" Jody Aufrichtig "
Jody Aufrichtig
Director and Executive Chairman